rss
BMJ Case Reports 2009; doi:10.1136/bcr.04.2009.1732
  • Unexpected outcome (positive or negative) including adverse drug reactions

Progression of viraemia during treatment with infliximab in a patient with rheumatoid arthritis and chronic hepatitis C infection

  1. Hiroshi Uda1,
  2. Makihiko Kuhara2,
  3. Norihiro Nishimoto3,
  4. Osamu Saiki2
  1. 1
    Sakai Onshinkai Hospital, Department of Rheumatology, Fukaishimizucho 2140-1, Naka-ku, Sakai City, Osaka, 599-8273, Japan
  2. 2
    Osaka Prefecture University, Department of Rehabilitation, Habikino 3-7-30, Habikino, Osaka, 583-8555, Japan
  3. 3
    Wakayama Prefecture Medical College, Department of Immunoregulation, Saito Bioinnovation Center 105, Saitoasagi, 7-7-20, Ibaraki, Osaka, 567-0085, Japan
  1. Osamu Saiki, osaiki{at}rehab.osakafu-u.ac.jp
  • Published 10 August 2009

Summary

Tumour necrosis factor α (TNFα) antagonists are effective for the treatment of rheumatoid arthritis (RA), but concerns remain about their safety in the presence of hepatitis C virus (HCV) infection. The influence of treatment with the TNFα antagonist infliximab on levels of HCV viraemia and serum transaminases in a 38-year-old patient with RA and HCV was examined to assess the safety of the drug. After starting infliximab treatment, the patient’s clinical symptoms improved significantly (28-joint Disease Activity Score (DAS28) of less than 3) and levels of transaminases were normal. At the 14th injection of infliximab, the levels of HCV viraemia and transaminases were significantly elevated. After stopping the infliximab injections, the levels of transaminases returned to normal with infusion of glycyrrhizinate derivatives within 3 months. Evidence is provided of aggravation of serum transaminases and progression of viraemia during treatment with infliximab in a patient with RA and HCV infection.

Footnotes

  • Competing interests: None.

  • Patient consent: Patient/guardian consent was obtained for publication.

Register for free content

The full text of all Editor's Choice articles and summaries of every article are free without registration

The full text of Images in ... articles are free to registered users

Only fellows can access the full text of case reports (apart from Editor's Choice) - become a fellow today, or encourage your institution to, so that together we can grow and develop this resource

Don't forget to sign up for content alerts so you keep up to date with all the case reports as they are published, and let us know what you think by commenting on the Editor's blog

Navigate This Article